Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.

ABSTRACT:

Objectives

Extensive but fragmented data from existing studies were used to describe the drug-drug interaction between rifabutin and HIV PIs and predict doses achieving recommended therapeutic exposure for rifabutin in patients with HIV-associated TB, with concurrently administered PIs.

Methods

Individual-level data from 13 published studies were pooled and a population analysis approach was used to develop a pharmacokinetic model for rifabutin, its main active metabolite 25-O-desacetyl rifabutin (des-rifabutin) and drug-drug interaction with PIs in healthy volunteers and patients who had HIV and TB (TB/HIV).

Results

Key parameters of rifabutin affected by drug-drug interaction in TB/HIV were clearance to routes other than des-rifabutin (reduced by 76%-100%), formatio

SUBMITTER: Hennig S 

PROVIDER: S-EPMC4830412 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature